Amarin announced that the Company received a Decision to Grant from the European Patent Office or EPO, for a new patent covering VAZKEPA or icosapent ethyl, that will extend VAZKEPA exclusivity eight additional years into 2039. In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO. Collectively, these patents cover both the protocol and results from the landmark REDUCE-IT outcomes study, providing an extended and strengthened exclusivity position for VAZKEPA within the Company’s European market. “Today’s announcement extends the commercial runway for VAZKEPA in Europe by eight additional years, which enhances the potential impact that this product can have for patients and the growth potential for VAZKEPA across the continent,” said Patrick Holt, President & CEO, Amarin. “Moving forward, we will continue to rigorously defend our IP rights and explore any possibilities to strengthen Amarin’s patents and patent families around the world.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRN:
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
- Amarin to present research on benefits of VASCEPA/VAZKEPA
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
- Largest borrow rate increases among liquid names
- Amarin Corporation Plc’s New Competition Risk – A Cause for Worry?